舒泰神(300204.SZ)：BDB-001注射液(ANCA相关性血管炎适应症)获得III期临床研究总结报告

Core Viewpoint - Shuyou Shen (300204.SZ) has announced positive results from the I/II phase clinical trial of BDB-001 injection for ANCA-associated vasculitis (AAV), demonstrating good disease control and safety [1] Group 1: Clinical Trial Results - The I/II phase clinical trial of BDB-001 injection has shown effective disease remission control [1] - The product exhibits good safety and tolerability [1] - Significant clinical advantages in hormone reduction have been confirmed, particularly in the complete remission rate [1] Group 2: Future Plans - Based on current data, the company plans to actively advance to the III phase clinical trial to further validate the clinical benefits for AAV patients [1]